Cover Image
市場調查報告書

多發性囊胞腎 (PKD):開發中產品分析

Polycystic Kidney Disease - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 192782
出版日期 內容資訊 英文 108 Pages
訂單完成後即時交付
價格
Back to Top
多發性囊胞腎 (PKD):開發中產品分析 Polycystic Kidney Disease - Pipeline Review, H1 2018
出版日期: 2018年04月30日 內容資訊: 英文 108 Pages
簡介

所謂多發性囊胞腎 (PKD) ,主要是在腎臟內部密集產生囊胞的疾病。主要的前兆,是高血壓和背、側腹的疼痛,頭痛,血尿,頻尿,腎功能衰竭等。易罹病素質中包含年齡和家族病史等。主要的治療藥有抗高血壓藥和利尿劑等。

本報告提供全球各國的多發性囊胞腎(多囊性腎臟病)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

多發性囊胞腎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品:各企業
  • 開發中產品:各大學/機關
  • 企業開發中的產品
  • 大學/機關研究中的產品

多發性囊胞腎:治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發多發性囊胞腎的治療藥的企業

  • Angion Biomedica Corp
  • Aptevo Therapeutics Inc
  • Celgene Corp
  • Conatus Pharmaceuticals Inc
  • DiscoveryBiomed Inc
  • Endocyte Inc
  • IC-MedTech Inc
  • Ipsen SA
  • Kadmon Corp LLC
  • Madrigal Pharmaceuticals Inc.
  • ManRos Therapeutics
  • Metabolic Solutions Development Company LLC
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • 大塚集團
  • Q BioMed Inc
  • Regulus Therapeutics Inc
  • XORTX Pharma Corp

藥物簡介

多發性囊胞腎:暫停中的計劃

多發性囊胞腎:開發中止的產品

多發性囊胞腎:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10399IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2018, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 4, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Polycystic Kidney Disease - Overview
  • Polycystic Kidney Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Polycystic Kidney Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Polycystic Kidney Disease - Companies Involved in Therapeutics Development
  • Angion Biomedica Corp
  • Celgene Corp
  • Conatus Pharmaceuticals Inc
  • DiscoveryBiomed Inc
  • Endocyte Inc
  • Genzyme Corp
  • IC-MedTech Inc
  • Ipsen SA
  • Kadmon Corp LLC
  • ManRos Therapeutics
  • Metabolic Solutions Development Company LLC
  • Mironid Ltd
  • NovaTarg Therapeutics Inc
  • Otsuka Holdings Co Ltd
  • Q BioMed Inc
  • Reata Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • Polycystic Kidney Disease - Drug Profiles
  • (sodium ascorbate + menadione sodium bisulfite) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANG-3070 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bardoxolone methyl - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CR-8 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DBM-43H11 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Cystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Polycystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EC-0371 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ibiglustat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IDN-8050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JP-153 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lanreotide acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lixivaptan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • menadione sodium bisulfite - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MSDC-0160 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxypurinol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pyrimethamine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RGLS-4326 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ricolinostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit STAT3 for Oncology and Polycystic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tesevatinib tosylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tolvaptan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Polycystic Kidney Disease - Dormant Projects
  • Polycystic Kidney Disease - Discontinued Products
  • Polycystic Kidney Disease - Product Development Milestones
  • Featured News & Press Releases
  • Feb 27, 2018: Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
  • Dec 19, 2017: Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
  • Nov 13, 2017: Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease
  • Nov 09, 2017: FDA Accepts Otsuka's Resubmission To Support A Regulatory Review Of Tolvaptan In The Treatment Of ADPKD
  • Nov 06, 2017: Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Nov 01, 2017: Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting
  • Oct 27, 2017: Otsuka to Host Web Briefing on Tolvaptan Phase 3 Trial Results in Polycystic Kidney Disease
  • Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease
  • Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors
  • Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326
  • May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S
  • May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.
  • Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan
  • Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD
  • Jan 30, 2017: Mironid announces additional non-dilutive funding through an Early Stage Award from Innovate UK's Biomedical Catalyst 2016
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Polycystic Kidney Disease, H1 2018
  • Table 2: Number of Products under Development by Companies, H1 2018
  • Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 4: Number of Products under Development by Universities/Institutes, H1 2018
  • Table 5: Products under Development by Companies, H1 2018
  • Table 6: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Table 7: Products under Development by Universities/Institutes, H1 2018
  • Table 8: Number of Products by Stage and Target, H1 2018
  • Table 9: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
  • Table 10: Number of Products by Stage and Mechanism of Action, H1 2018
  • Table 11: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
  • Table 12: Number of Products by Stage and Route of Administration, H1 2018
  • Table 13: Number of Products by Stage and Molecule Type, H1 2018
  • Table 14: Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H1 2018
  • Table 15: Polycystic Kidney Disease - Pipeline by Celgene Corp, H1 2018
  • Table 16: Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H1 2018
  • Table 17: Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H1 2018
  • Table 18: Polycystic Kidney Disease - Pipeline by Endocyte Inc, H1 2018
  • Table 19: Polycystic Kidney Disease - Pipeline by Genzyme Corp, H1 2018
  • Table 20: Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H1 2018
  • Table 21: Polycystic Kidney Disease - Pipeline by Ipsen SA, H1 2018
  • Table 22: Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H1 2018
  • Table 23: Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H1 2018
  • Table 24: Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H1 2018
  • Table 25: Polycystic Kidney Disease - Pipeline by Mironid Ltd, H1 2018
  • Table 26: Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H1 2018
  • Table 27: Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H1 2018
  • Table 28: Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H1 2018
  • Table 29: Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, H1 2018
  • Table 30: Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H1 2018
  • Table 31: Polycystic Kidney Disease - Dormant Projects, H1 2018
  • Table 32: Polycystic Kidney Disease - Discontinued Products, H1 2018

List of Figures

  • Figure 1: Number of Products under Development for Polycystic Kidney Disease, H1 2018
  • Figure 2: Number of Products under Development by Companies, H1 2018
  • Figure 3: Number of Products by Top 10 Targets, H1 2018
  • Figure 4: Number of Products by Stage and Top 10 Targets, H1 2018
  • Figure 5: Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Figure 7: Number of Products by Routes of Administration, H1 2018
  • Figure 8: Number of Products by Stage and Routes of Administration, H1 2018
  • Figure 9: Number of Products by Top 10 Molecule Types, H1 2018
  • Figure 10: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top